Can Albumin Bilirubin Ratio Predict Survival in Metastatic Gastric Cancer?
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objectives: This study evaluated the prognostic significance of the new index designed with albumin and bilirubin ratio (ABR) in patients with metastatic gastric cancer (GC).
Methods: The data of patients with metastatic gastric cancer followed in the medical oncology clinic between February 2012, and May 2020 were retrospectively reviewed. ABR was defined by dividing the albumin level by the bilirubin level.
Results: Overall survival (OS) of all patients was reported as 12.9 months (95% CI, 10.9-14.9). The effect of ABR on survival time was not found statistically significant (p=0.462; p>0.05).
Conclusion: This study evaluated the prognostic significance of the new index designed with ABR in patients with metastatic gastric cancer (GC), but no statistically significant result was obtained. Simple, accessible, and inexpensive tests showing recurrence, treatment response, and prognosis of GC are needed. Studies should be conducted with a more significant number of patient populations to determine the role of ABR in GC